Department of Microbiology and Center of Infectious Diseases, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.
Department of Infectious Diseases, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.
Vaccine. 2017 Dec 4;35(48 Pt B):6627-6633. doi: 10.1016/j.vaccine.2017.10.032. Epub 2017 Nov 1.
Antiviral therapy has been documented to reduce perinatal transmission of hepatitis B virus (HBV) in highly viremic mothers. This large prospective cohort study conducted in China aims to delineate the maternal viral threshold for consideration of antiviral prophylaxis in settings with limited resources.
A total of 1177 mother-infant pairs with positive maternal hepatitis B surface antigen (HBsAg) under current passive-active prophylaxis regimen were enrolled from community health centers in Jiangsu and Henan provinces, China. Maternal hepatitis B e antigen (HBeAg) status and viral load were tested at 36-40 weeks of gestation. Post-vaccination serologic testing was performed at 7 and 12 months of age.
HBeAg-positive mothers (419/1177; 35.6%) had significantly higher viral loads, compared with HBeAg-negative mothers (758/1177; 64.4%) (8.12 vs. 2.69 log IU/mL, p < .0001). Twenty infants, born to HBeAg-positive mothers with high viral loads (median, 8.38; range: 7.82-9.22 log IU/mL), were infected at 7 months of age. In contrast, none of the HBeAg-negative mothers transmitted HBV to their offspring. After adjustment for the other risk factor, a higher maternal viral load was significantly associated with a higher risk of transmission (adjusted odds ratio, 3.78; 95% confidence interval: 1.46-9.81; p = .006). The rates of passive-active immunoprophylaxis failure were 0.0% (0/789), 0.0% (0/27), 0.0% (0/32) and 6.1% (20/329) at maternal viral loads of <5, 5-6, 6-7 and ≥7 log IU/mL, respectively. The antibody to hepatitis B surface antigen (anti-HBs) response rate was 98.4% (1138/1157) at 7 months of age.
Results from this study indicate that the maternal viral threshold associated with perinatal transmission of HBV is 7 log IU/mL, which may be appropriate for consideration of antiviral prophylaxis in settings with limited resources.
抗病毒治疗已被证明可降低高病毒血症母亲乙型肝炎病毒(HBV)的围产期传播。本项在中国进行的大型前瞻性队列研究旨在描绘在资源有限的情况下,考虑抗病毒预防的母体病毒阈值。
本研究共纳入 1177 对在江苏省和河南省社区卫生服务中心接受当前被动-主动预防方案的 HBsAg 阳性母婴。在妊娠 36-40 周时检测母婴乙型肝炎 e 抗原(HBeAg)状态和病毒载量。在 7 个月和 12 个月时进行疫苗接种后血清学检测。
HBeAg 阳性母亲(1177 例中的 419 例,35.6%)的病毒载量明显高于 HBeAg 阴性母亲(1177 例中的 758 例,64.4%)(8.12 vs. 2.69 log IU/mL,p < 0.0001)。在 7 个月时,20 名 HBeAg 阳性母亲(中位病毒载量 8.38;范围:7.82-9.22 log IU/mL)所生的婴儿感染。相比之下,HBeAg 阴性母亲无一例将 HBV 传播给后代。在调整其他危险因素后,较高的母体病毒载量与较高的传播风险显著相关(调整后的优势比,3.78;95%置信区间:1.46-9.81;p = 0.006)。在病毒载量<5、5-6、6-7 和≥7 log IU/mL 时,被动-主动免疫预防失败率分别为 0.0%(0/789)、0.0%(0/27)、0.0%(0/32)和 6.1%(20/329)。7 个月时乙型肝炎表面抗原抗体(抗-HBs)的反应率为 98.4%(1138/1157)。
本研究结果表明,与 HBV 围产期传播相关的母体病毒阈值为 7 log IU/mL,这可能适合在资源有限的情况下考虑抗病毒预防。